FDA approves VYALEV for adults living with advanced parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Strokes are affecting approximately 1.8 million people annually
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Subscribe To Our Newsletter & Stay Updated